Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Rhea-AI Summary

Enlivex (Nasdaq: ENLV) will present Phase IIa 3-month and 6-month clinical data for Allocetra at the OARSI 2026 World Congress (April 23-26, 2026) in West Palm Beach.

Posters report statistically significant, clinically meaningful reductions in pain and improved function versus placebo in idiopathic age-related KOA patients ≥60, plus pharmacological data on Allocetra's immunomodulating mechanism.

Positive

• Phase IIa data show statistically significant pain reduction versus placebo at 3 and 6 months
• Phase IIa data show clinically meaningful functional improvement versus placebo at 3 and 6 months
• Allocetra pharmacology poster provides mechanistic data supporting a novel immunomodulating mechanism
• Data to be presented at the leading international OARSI 2026 World Congress

Negative

• Results derive from a Phase IIa trial, not a pivotal/registration study
• No safety or long-term durability metrics beyond six months are reported in this announcement

News Market Reaction – ENLV

+2.04%

+2.04% Session close to close

In the Apr 23 session, ENLV gained 2.04%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Phase IIa data for Allocetra™ in moderate-to-severe knee osteoarthritis...

Analysis

This announcement highlights Phase IIa data for Allocetra™ in moderate-to-severe knee osteoarthritis, showing clinically meaningful, statistically significant pain reduction and functional improvement at three and six months in patients aged ≥60, a group representing more than 50% of the KOA market. It builds on recent Phase 2b regulatory clearances and Enlivex’s broader strategy. Investors may watch for full data details, Phase 2b enrollment progress, and any further capital markets activity linked to the existing F-3 resale registration.

Key Figures

Phase IIa endpoints: 3-month clinical data Phase IIa endpoints: 6-month clinical data Patient age: ≥60 years +5 more

8 metrics

Phase IIa endpoints 3-month clinical data Allocetra™ in moderate-to-severe knee osteoarthritis

Phase IIa endpoints 6-month clinical data Allocetra™ in moderate-to-severe knee osteoarthritis

Patient age ≥60 years Idiopathic age-related osteoarthritis patients

Market segment More than 50% of KOA market Idiopathic age-related osteoarthritis patients

Trial identifier NCT06233474 Randomized Phase IIa Allocetra™ KOA study

Abstract ID 4466183 Efficacy at 6 months poster

Poster Number 405 Allocetra™ Phase IIa efficacy poster

Abstract ID 4466242 Pharmacological characterization poster

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Regulatory trial approval	Positive	+0.3%	Danish regulator approved Phase 2b Allocetra trial in knee osteoarthritis.
Apr 08	Tokenization partnership	Positive	+12.0%	Ondo Finance launched ENLVon tokenized shares for global digital access.
Mar 26	Prediction markets update	Positive	-9.2%	Rain protocol AI interface and $5 million grant program tied to RAIN.
Mar 25	Earnings release	Positive	+9.1%	Reported $1.23 billion net income and EPS of $25.48 for 2025.
Mar 24	Financing & buyback	Positive	-0.9%	Closed $21M convertible note, bought RAIN tokens, approved $20M buyback.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ENLV news has mostly been positive with mixed price reactions: three aligned upside moves and two downside divergences.

Recent Company History

Over the last month, Enlivex has combined clinical and capital markets developments. On Mar 24 it announced a $21 million convertible note, a RAIN token purchase and a $20 million buyback program, followed by strong 2025 results on Mar 25 with net income of $1.23 billion. Tokenization news on Apr 8 and Danish Phase 2b trial approval on Apr 21 continued this trajectory. Today’s Phase IIa Allocetra™ knee osteoarthritis efficacy data at three and six months fits the ongoing build‑out of its osteoarthritis program.

Key Terms

knee osteoarthritis, idiopathic age-related osteoarthritis, pharmacological characterization, immunomodulating mechanism of action, +4 more

8 terms

knee osteoarthritis medical

"Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA)."

A degenerative condition in which the cushioning tissue in the knee joint gradually wears away, causing pain, stiffness and reduced mobility. For investors it matters because it creates steady demand for medicines, medical devices, surgeries and rehabilitation services, influences healthcare costs and reimbursement decisions, and drives clinical trials and regulatory reviews—similar to how a worn-out shock absorber creates a predictable need for repairs or replacements.

idiopathic age-related osteoarthritis medical

"in idiopathic age-related osteoarthritis patients (≥60 years)"

A chronic joint condition where cartilage breaks down with advancing age and the exact cause is not known, leading to pain, stiffness and reduced mobility; think of joints as hinges that gradually wear out without a single identifiable trigger. Investors care because it drives sustained demand for treatments, medical devices, long-term care and related services, so advances in therapies or shifts in prevalence can affect healthcare spending, company revenues and market opportunities across pharmaceuticals, device makers and care providers.

pharmacological characterization medical

"present comprehensive pharmacological characterization data supporting the novel"

Pharmacological characterization is the process of testing and describing how a drug works in the body—what it targets, how strongly it acts, how long it lasts, and what side effects or interactions it may cause. For investors, this is like a detailed test drive and safety report: it helps predict whether the drug is likely to be effective, safe, and competitive, reducing uncertainty about future clinical success and commercial value.

immunomodulating mechanism of action medical

"supporting the novel immunomodulating mechanism of action of AllocetraTM."

An immunomodulating mechanism of action describes how a medicine or therapy changes the behavior of the immune system—either turning up, dialing down, or redirecting immune responses—similar to how a thermostat adjusts a room’s temperature or a conductor guides an orchestra. For investors, this matters because the way a product affects immunity drives its potential effectiveness, safety profile, regulatory hurdles, market size, and likelihood of approval or adoption.

randomized, double-blind, placebo-controlled medical

"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA TRIAL OF ALLOCETRATM"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

intra-articular medical

"AN INNOVATIVE INTRA-ARTICULAR APOPTOTIC CELL THERAPY IN KNEE OSTEOARTHRITIS"

An intra-articular treatment is one that is injected directly into a joint space, such as the knee or shoulder, to deliver medication or therapy right where the problem is. For investors, this matters because intra-articular delivery can improve effectiveness and reduce systemic side effects compared with pills or injections elsewhere in the body, affecting a drug’s clinical value, regulatory pathway, market appeal, and reimbursement prospects.

apoptotic cell therapy medical

"AN INNOVATIVE INTRA-ARTICULAR APOPTOTIC CELL THERAPY IN KNEE OSTEOARTHRITIS"

Apoptotic cell therapy uses specially prepared dying cells to calm or retrain the immune system, much like sending a peaceful messenger to stop an overactive guard dog. It matters to investors because this approach aims to treat autoimmune diseases, inflammation and transplant rejection with a fundamentally different mechanism than conventional drugs, creating potential new markets but also carrying clinical trial, manufacturing and regulatory risks that affect value and timelines.

macrophage reprogramming cell therapy medical

"A NOVELMACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA ARTICULARTREATMENT"

A therapy that uses living immune cells called macrophages, taken from a patient or donor and altered outside the body so they behave differently when returned, with the goal of fighting disease or repairing tissue. Think of it like retraining frontline workers to perform a new job in the body. Investors care because successful programs can create new drug categories, carry high development costs and regulatory hurdles, and therefore offer both large upside and significant risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA.

The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (NCT06233474) for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA).  The Phase IIa data demonstrated clinically meaningful and statistically significant improvement of the Allocetra™-treated arm in reduction of pain and improvement of function, compared to the control placebo arm, in idiopathic age-related osteoarthritis patients (≥60 years), representing more than 50% of the total KOA market. 

The data will be presented by Prof. Philip Conaghan, Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. Professor Conaghan is an international leader in osteoarthritis and musculoskeletal imaging, who has authored more than 700 publications and chaired multiple global guidelines and trial initiatives. In addition, the Company will present comprehensive pharmacological characterization data supporting the novel immunomodulating mechanism of action of Allocetra^TM.

Oren Hershkovitz, Ph.D, CEO of Enlivex, commented "We are pleased that the OARSI 2026 team selected Enlivex to present this data at the 2026 World Congress on Osteoarthritis, which is the leading international congress on the topic of osteoarthritis. We look forward to presenting the depth of our clinical and pharmacological program for Allocetra™, including three-month and six-month efficacy and mechanistic characterization data behind our unique approach to addressing inflammatory, age-related joint disease."

Poster Presentations:

Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA TRIAL OF ALLOCETRA^TM - AN INNOVATIVE INTRA-ARTICULAR APOPTOTIC CELL THERAPY IN KNEE OSTEOARTHRITIS DEMONSTRATES DURABLE EFFICACY AT 6 MONTHS (NCT06233474)

• Abstract ID: 4466183
• Poster Number: 405
• Date & Time: April 24 & 25 2026 | 03:30 PM – 04:15 PM ET

Title: PHARMACOLOGICAL CHARACTERIZATION OF ALLOCETRA^TM; A NOVELMACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA ARTICULARTREATMENT IN OSTEOARTHRITIS

• Abstract ID: 4466242
• Poster Number: 549
• Date & Time: April 24 & 25 2026 | 03:30 PM – 04:15 PM ET

About Enlivex (Nasdaq: ENLV)

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.

In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com

FAQ

What Phase IIa Allocetra data will Enlivex (ENLV) present at OARSI 2026?

Enlivex will present 3-month and 6-month Phase IIa clinical endpoints for Allocetra in knee osteoarthritis. According to the company, posters report statistically significant pain reduction and functional improvement versus placebo in patients ≥60 years.

When and where will Enlivex present the Allocetra posters at OARSI 2026?

The Allocetra posters will be shown at OARSI 2026 in West Palm Beach, April 23-26, 2026. According to the company, poster sessions are scheduled April 24–25, 2026 at 03:30 PM–04:15 PM ET.

What patient population was included in Enlivex's Allocetra Phase IIa trial (ENLV)?

The trial enrolled idiopathic age-related knee osteoarthritis patients, primarily aged ≥60 years. According to the company, this age group represents more than 50% of the total KOA market in the presented data set.

What additional scientific data will Enlivex present about Allocetra at OARSI 2026?

Enlivex will present pharmacological characterization data supporting Allocetra's immunomodulating, macrophage-reprogramming mechanism. According to the company, this mechanistic poster complements the clinical efficacy findings at three and six months.

Who will present Enlivex's Allocetra clinical data at the OARSI World Congress?

Professor Philip Conaghan will present the clinical poster sessions for Allocetra at OARSI 2026. According to the company, he is a consultant rheumatologist and director at the NIHR Leeds Biomedical Research Centre.